Key result
BTX-mCIMT improves upper limb motor function and daily activities more than BTX-ICT at 4 weeks.
RCT (n=64)
Randomly allocated
Answers are grounded in this paper and cite their sources.
Stroke is the second leading cause of mortality worldwide and one of the main causes of adult disability. Many studies have suggested that combination therapies provide better outcomes in patients with stroke than monotherapies. The combination of botulinum-A toxin (BTX) injection with rehabilitation methods, such as modified constraint-induced movement therapy (BTX-mCIMT), has emerged as a highly promising intervention for promoting motor recovery after stroke. Thus, the present study compared the effectiveness of the combination of BTX with high-dose conventional therapy (BTX-ICT) and BTX-mCIMT for improving motor recovery and reducing spasticity of the upper limb in patients with stroke. This study recruited 64 patients with stroke. The patients were randomly allocated to two groups, namely, BTX-ICT and BTX-mCIMT. Modified Ashworth scale (MAS), Fugl-Meyer assessment (FMA), and Barthel index (BI) assessment scores were determined for the patients in both the groups before and at 4 weeks after the BTX injection. After four weeks of treatment, the MAS, FMA, and BI assessment scores of the patients in both groups were significantly higher than the scores before the treatments (P < 0.05). At the end of 4 weeks, the patients in the BTX-mCIMT group showed significantly higher mean FMA and BI assessment scores than the patients in the BTX-ICT group (P < 0.05). However, no significant statistical difference was observed in the MAS score of the patients in the two groups (P > 0.05). Our results indicated that while both BTX-mCIMT and BTX-ICT promoted motor function recovery in patients with stroke, BTX-mCIMT exerted higher therapeutic effects than BTX-ICT on motor function recovery and in the activities of daily living of patients with stroke.
No takes yet. Share an insight, caveat, or question.
Nasb et al. (2019) conducted an RCT in Stroke (n=64). Botulinum-A toxin with modified constraint-induced movement therapy (BTX-mCIMT) vs. Botulinum-A toxin with intensive conventional therapy (BTX-ICT) was evaluated on Modified Ashworth scale (MAS), Fugl-Meyer assessment (FMA), and Barthel index (BI) scores at 4 weeks (p=<0.05). BTX-mCIMT improved upper limb motor function and daily living activities significantly more than BTX-ICT at 4 weeks (P<0.05), with no significant difference in spasticity reduction (P>0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: